Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in B-cell Lymphomas with Hepatitis B
NCT02991638Phase 3Unknown
- Sponsor
- The University of Hong Kong
- Start
- Nov 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), Waldenstrom macroglobulinemia (WM), sponsored by The University of Hong Kong. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02991638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991638.